We invest continuously in foundational mRNA capabilities—from molecular design and delivery engineering to precise control of immune effects—forming a platform that is verifiable, scalable, and regulator-ready.
Driven by real programs, we translate scientific breakthroughs into mRNA medicines and vaccines that can be manufactured at scale, delivered reliably, and made broadly accessible—advancing the boundaries of human health and longevity.
Systematically tune expression strength, duration, and immune behavior to build reusable and verifiable design capability.
Across key variables such as cap, UTR, poly(A), and modification strategies, we establish an iterative design space and standardized validation framework.
LNP-centered delivery engineering across biodistribution, cellular entry, and release mechanisms.
We converge on efficiency, safety, and manufacturability to support productization across indications and routes of administration.
Improve immune quality within safety boundaries across prophylactic vaccines and therapeutic immunology.
We translate innate/adaptive control points into engineerable formulation and process variables, enabling interpretable immune “tuning.”
Integrate process parameters, critical quality attributes (CQAs), and scale-up strategy early to ensure consistency and long-term manufacturability.
Guided by QbD, we connect development evidence seamlessly to regulatory submission and commercial production.
Translate requirements into engineering constraints with consistent, explainable risk control and communication logic.
With quantifiable comparability and method validation, we strengthen batch-to-batch and cross-scenario reviewability.
Design the platform around clinical endpoints and converge nonclinical evidence, CMC, and regulatory strategy into a verifiable, repeatable delivery path.
We establish a continuously improving translation loop around key clinical decisions—population, dose, immune readouts, and safety boundaries.
